Linqmed Inc. announced that it has received ¥680 million in round of funding on December 22, 2023. The transaction included the participation from new investors Mizuho Capital Co., Ltd., IWABUCHI YAKUHIN Inc., PeptiDream Inc., Taisho Pharmaceutical Holdings Co., Ltd., Green Core Co., Ltd., Shiratori Pharmaceutical Co., Ltd., DBJ Capital Co., Ltd. and Osaka Kansai Expo Revitalization Fund, a co- fund managed by Bio-Sight Capital Co., Ltd., SBI Chiki Kasseika Shien Co., Ltd. and SBI Regional Business Investment Co., Ltd. The company will issue J-KISS Stock Acquisition Rights. The company has raised ¥930 million funding till the date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,954 JPY | -0.43% | +0.72% | +31.42% |
07/05 | Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold | MT |
30/04 | Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.42% | 1.63B | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.23% | 22.25B | |
-13.14% | 22.09B | |
-7.82% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 4587 Stock
- News PeptiDream Inc.
- Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors